Irbesart

Article Contents ::

Details About Generic Salt ::  Irbesart

Main Medicine Class:: Antihypertensive, Angiotensin II antagonist   

(ihr-beh-SAHR-tan)
Avapro
Tablets: 75 mg
Tablets: 150 mg
Tablets: 300 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension; nephropathy in type 2 diabetes.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Hypertension

Adults: PO Start with 150 mg once daily; then titrate to 300 mg once daily as necessary.

Children (13 to 16 yr): PO Start with 150 mg once daily; then titrate patients requiring a further reduction in BP to 300 mg once daily.

Children (6 to 12 yr): PO Start with 75 mg once daily; then titrate patients requiring a further reduction in BP to 150 mg once daily.

Nephropathy in Type 2 Diabetes

Adults PO Titrate dose to 300 mg once daily.

Volume- and Salt-Depleted Patients

PO Start with 75 mg.

 

 Interactions

Lithium:

Plasma concentrations my be increased by irbesartan, resultingin an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CARDIOVASCULAR: Chest pain; tachycardia; edema. CNS: Headache; anxiety/nervousness; dizziness. GI: Diarrhea; dyspepsia/heartburn; abdominal pain; nausea/vomiting. RESPIRATORY: Upper respiratory infection; influenza; pharyngitis; rhinitis; sinus abnormality OTHER: Musculoskeletal pain/trauma; fatigue; UIT; rash.

 

 Precautions

Pregnancy: Category C (first trimester); Category D (second and third trimesters). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established in children younger than 6 yr. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hypotension: Initiation of antihypertensive therapy may cause symptomatic hypotension in patients with intravascular volume or sodium-depletion.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Give prescribed dose once daily with or without food.
  • Administer alone or in combination with other antihypertensives.
  • Do not administer to pregnant women because fetal and neonatal morbidity and death can occur.
  • Administer with caution and reduced dosage in patients with possible depletion of intravascular volume or history of hepatic impairment.
  • Store tablets at controlled room temperature (59° to 86°F).

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note history of anuria, lupus erythematosus, or kidney or liver disease.
  • Ensure that serum electrolytes are monitored periodically.
  • Monitor and record BP and pulse. Should hypotension result, old medication and notify health care provider.
  • Take safety precautionsif orthostatic hypotension occurs.
  • Monitor for sighns of hypersensitivity including angioedema involving swelling of the face, lips, eyelids, and tongue. Discontinue medication and notify health care provider immediately if noted.

 

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient to take prescribed dose once daily, without regard to meals.
  • Advise patient to try to take each dose at about the same time each day.
  • Inform patient that drug controls, but does not cure, hypertension, and to continue taking drug as prescribed even when BP is not elevated.
  • Caution patient not to change the dose or stop taking unless advised by health care provider.
  • Instruct patient in BP and pulse measurement skills.
  • Advise patient to monitor and record BP and pulse at home and to inform health care provider should abnormal measurements be noted. Also advise patient to take record of BP and pulse to each follow-up visit.
  • Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to lie or sit down if they experience dizziness or lightheadedness when standing.
  • Caution patient that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP, resulting in lightheadedness or fainting.
  • Emphasize to hypertensive patient importance of other modalities on BP: weight control, regular exercise, smoking cessation, moderate intake of alohol and salt.
  • Advise patient to contact health care provider if pregnant, planning to become pregnant, or breastfeeding.
  • Instruct patient to stop taking drug and immediately report any of these symptoms to health care provider: fainting; swelling of the face, lips, eyelids, or tongue.
  • Caution patient to not take any prescription or OTC medications, salt substitutes, or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and lab tests may be required to monitor therapy and to keep appointments.

 

Drugs Class ::

(ihr-beh-SAHR-tan)
Avapro
Tablets: 75 mg
Tablets: 150 mg
Tablets: 300 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension; nephropathy in type 2 diabetes.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Hypertension

Adults: PO Start with 150 mg once daily; then titrate to 300 mg once daily as necessary.

Children (13 to 16 yr): PO Start with 150 mg once daily; then titrate patients requiring a further reduction in BP to 300 mg once daily.

Children (6 to 12 yr): PO Start with 75 mg once daily; then titrate patients requiring a further reduction in BP to 150 mg once daily.

Nephropathy in Type 2 Diabetes

Adults PO Titrate dose to 300 mg once daily.

Volume- and Salt-Depleted Patients

PO Start with 75 mg.

 

 Interactions

Lithium:

Plasma concentrations my be increased by irbesartan, resultingin an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CARDIOVASCULAR: Chest pain; tachycardia; edema. CNS: Headache; anxiety/nervousness; dizziness. GI: Diarrhea; dyspepsia/heartburn; abdominal pain; nausea/vomiting. RESPIRATORY: Upper respiratory infection; influenza; pharyngitis; rhinitis; sinus abnormality OTHER: Musculoskeletal pain/trauma; fatigue; UIT; rash.

 

 Precautions

Pregnancy: Category C (first trimester); Category D (second and third trimesters). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established in children younger than 6 yr. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hypotension: Initiation of antihypertensive therapy may cause symptomatic hypotension in patients with intravascular volume or sodium-depletion.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Give prescribed dose once daily with or without food.
  • Administer alone or in combination with other antihypertensives.
  • Do not administer to pregnant women because fetal and neonatal morbidity and death can occur.
  • Administer with caution and reduced dosage in patients with possible depletion of intravascular volume or history of hepatic impairment.
  • Store tablets at controlled room temperature (59° to 86°F).

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note history of anuria, lupus erythematosus, or kidney or liver disease.
  • Ensure that serum electrolytes are monitored periodically.
  • Monitor and record BP and pulse. Should hypotension result, old medication and notify health care provider.
  • Take safety precautionsif orthostatic hypotension occurs.
  • Monitor for sighns of hypersensitivity including angioedema involving swelling of the face, lips, eyelids, and tongue. Discontinue medication and notify health care provider immediately if noted.

 

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient to take prescribed dose once daily, without regard to meals.
  • Advise patient to try to take each dose at about the same time each day.
  • Inform patient that drug controls, but does not cure, hypertension, and to continue taking drug as prescribed even when BP is not elevated.
  • Caution patient not to change the dose or stop taking unless advised by health care provider.
  • Instruct patient in BP and pulse measurement skills.
  • Advise patient to monitor and record BP and pulse at home and to inform health care provider should abnormal measurements be noted. Also advise patient to take record of BP and pulse to each follow-up visit.
  • Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to lie or sit down if they experience dizziness or lightheadedness when standing.
  • Caution patient that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP, resulting in lightheadedness or fainting.
  • Emphasize to hypertensive patient importance of other modalities on BP: weight control, regular exercise, smoking cessation, moderate intake of alohol and salt.
  • Advise patient to contact health care provider if pregnant, planning to become pregnant, or breastfeeding.
  • Instruct patient to stop taking drug and immediately report any of these symptoms to health care provider: fainting; swelling of the face, lips, eyelids, or tongue.
  • Caution patient to not take any prescription or OTC medications, salt substitutes, or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and lab tests may be required to monitor therapy and to keep appointments.

Indications for Drugs ::

(ihr-beh-SAHR-tan)
Avapro
Tablets: 75 mg
Tablets: 150 mg
Tablets: 300 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension; nephropathy in type 2 diabetes.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Hypertension

Adults: PO Start with 150 mg once daily; then titrate to 300 mg once daily as necessary.

Children (13 to 16 yr): PO Start with 150 mg once daily; then titrate patients requiring a further reduction in BP to 300 mg once daily.

Children (6 to 12 yr): PO Start with 75 mg once daily; then titrate patients requiring a further reduction in BP to 150 mg once daily.

Nephropathy in Type 2 Diabetes

Adults PO Titrate dose to 300 mg once daily.

Volume- and Salt-Depleted Patients

PO Start with 75 mg.

 

 Interactions

Lithium:

Plasma concentrations my be increased by irbesartan, resultingin an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CARDIOVASCULAR: Chest pain; tachycardia; edema. CNS: Headache; anxiety/nervousness; dizziness. GI: Diarrhea; dyspepsia/heartburn; abdominal pain; nausea/vomiting. RESPIRATORY: Upper respiratory infection; influenza; pharyngitis; rhinitis; sinus abnormality OTHER: Musculoskeletal pain/trauma; fatigue; UIT; rash.

 

 Precautions

Pregnancy: Category C (first trimester); Category D (second and third trimesters). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established in children younger than 6 yr. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hypotension: Initiation of antihypertensive therapy may cause symptomatic hypotension in patients with intravascular volume or sodium-depletion.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Give prescribed dose once daily with or without food.
  • Administer alone or in combination with other antihypertensives.
  • Do not administer to pregnant women because fetal and neonatal morbidity and death can occur.
  • Administer with caution and reduced dosage in patients with possible depletion of intravascular volume or history of hepatic impairment.
  • Store tablets at controlled room temperature (59° to 86°F).

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note history of anuria, lupus erythematosus, or kidney or liver disease.
  • Ensure that serum electrolytes are monitored periodically.
  • Monitor and record BP and pulse. Should hypotension result, old medication and notify health care provider.
  • Take safety precautionsif orthostatic hypotension occurs.
  • Monitor for sighns of hypersensitivity including angioedema involving swelling of the face, lips, eyelids, and tongue. Discontinue medication and notify health care provider immediately if noted.

 

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient to take prescribed dose once daily, without regard to meals.
  • Advise patient to try to take each dose at about the same time each day.
  • Inform patient that drug controls, but does not cure, hypertension, and to continue taking drug as prescribed even when BP is not elevated.
  • Caution patient not to change the dose or stop taking unless advised by health care provider.
  • Instruct patient in BP and pulse measurement skills.
  • Advise patient to monitor and record BP and pulse at home and to inform health care provider should abnormal measurements be noted. Also advise patient to take record of BP and pulse to each follow-up visit.
  • Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to lie or sit down if they experience dizziness or lightheadedness when standing.
  • Caution patient that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP, resulting in lightheadedness or fainting.
  • Emphasize to hypertensive patient importance of other modalities on BP: weight control, regular exercise, smoking cessation, moderate intake of alohol and salt.
  • Advise patient to contact health care provider if pregnant, planning to become pregnant, or breastfeeding.
  • Instruct patient to stop taking drug and immediately report any of these symptoms to health care provider: fainting; swelling of the face, lips, eyelids, or tongue.
  • Caution patient to not take any prescription or OTC medications, salt substitutes, or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and lab tests may be required to monitor therapy and to keep appointments.

Drug Dose ::

(ihr-beh-SAHR-tan)
Avapro
Tablets: 75 mg
Tablets: 150 mg
Tablets: 300 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension; nephropathy in type 2 diabetes.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Hypertension

Adults: PO Start with 150 mg once daily; then titrate to 300 mg once daily as necessary.

Children (13 to 16 yr): PO Start with 150 mg once daily; then titrate patients requiring a further reduction in BP to 300 mg once daily.

Children (6 to 12 yr): PO Start with 75 mg once daily; then titrate patients requiring a further reduction in BP to 150 mg once daily.

Nephropathy in Type 2 Diabetes

Adults PO Titrate dose to 300 mg once daily.

Volume- and Salt-Depleted Patients

PO Start with 75 mg.

 

 Interactions

Lithium:

Plasma concentrations my be increased by irbesartan, resultingin an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CARDIOVASCULAR: Chest pain; tachycardia; edema. CNS: Headache; anxiety/nervousness; dizziness. GI: Diarrhea; dyspepsia/heartburn; abdominal pain; nausea/vomiting. RESPIRATORY: Upper respiratory infection; influenza; pharyngitis; rhinitis; sinus abnormality OTHER: Musculoskeletal pain/trauma; fatigue; UIT; rash.

 

 Precautions

Pregnancy: Category C (first trimester); Category D (second and third trimesters). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established in children younger than 6 yr. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hypotension: Initiation of antihypertensive therapy may cause symptomatic hypotension in patients with intravascular volume or sodium-depletion.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Give prescribed dose once daily with or without food.
  • Administer alone or in combination with other antihypertensives.
  • Do not administer to pregnant women because fetal and neonatal morbidity and death can occur.
  • Administer with caution and reduced dosage in patients with possible depletion of intravascular volume or history of hepatic impairment.
  • Store tablets at controlled room temperature (59° to 86°F).

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note history of anuria, lupus erythematosus, or kidney or liver disease.
  • Ensure that serum electrolytes are monitored periodically.
  • Monitor and record BP and pulse. Should hypotension result, old medication and notify health care provider.
  • Take safety precautionsif orthostatic hypotension occurs.
  • Monitor for sighns of hypersensitivity including angioedema involving swelling of the face, lips, eyelids, and tongue. Discontinue medication and notify health care provider immediately if noted.

 

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient to take prescribed dose once daily, without regard to meals.
  • Advise patient to try to take each dose at about the same time each day.
  • Inform patient that drug controls, but does not cure, hypertension, and to continue taking drug as prescribed even when BP is not elevated.
  • Caution patient not to change the dose or stop taking unless advised by health care provider.
  • Instruct patient in BP and pulse measurement skills.
  • Advise patient to monitor and record BP and pulse at home and to inform health care provider should abnormal measurements be noted. Also advise patient to take record of BP and pulse to each follow-up visit.
  • Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to lie or sit down if they experience dizziness or lightheadedness when standing.
  • Caution patient that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP, resulting in lightheadedness or fainting.
  • Emphasize to hypertensive patient importance of other modalities on BP: weight control, regular exercise, smoking cessation, moderate intake of alohol and salt.
  • Advise patient to contact health care provider if pregnant, planning to become pregnant, or breastfeeding.
  • Instruct patient to stop taking drug and immediately report any of these symptoms to health care provider: fainting; swelling of the face, lips, eyelids, or tongue.
  • Caution patient to not take any prescription or OTC medications, salt substitutes, or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and lab tests may be required to monitor therapy and to keep appointments.

Contraindication ::

(ihr-beh-SAHR-tan)
Avapro
Tablets: 75 mg
Tablets: 150 mg
Tablets: 300 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension; nephropathy in type 2 diabetes.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Hypertension

Adults: PO Start with 150 mg once daily; then titrate to 300 mg once daily as necessary.

Children (13 to 16 yr): PO Start with 150 mg once daily; then titrate patients requiring a further reduction in BP to 300 mg once daily.

Children (6 to 12 yr): PO Start with 75 mg once daily; then titrate patients requiring a further reduction in BP to 150 mg once daily.

Nephropathy in Type 2 Diabetes

Adults PO Titrate dose to 300 mg once daily.

Volume- and Salt-Depleted Patients

PO Start with 75 mg.

 

 Interactions

Lithium:

Plasma concentrations my be increased by irbesartan, resultingin an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CARDIOVASCULAR: Chest pain; tachycardia; edema. CNS: Headache; anxiety/nervousness; dizziness. GI: Diarrhea; dyspepsia/heartburn; abdominal pain; nausea/vomiting. RESPIRATORY: Upper respiratory infection; influenza; pharyngitis; rhinitis; sinus abnormality OTHER: Musculoskeletal pain/trauma; fatigue; UIT; rash.

 

 Precautions

Pregnancy: Category C (first trimester); Category D (second and third trimesters). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established in children younger than 6 yr. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hypotension: Initiation of antihypertensive therapy may cause symptomatic hypotension in patients with intravascular volume or sodium-depletion.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Give prescribed dose once daily with or without food.
  • Administer alone or in combination with other antihypertensives.
  • Do not administer to pregnant women because fetal and neonatal morbidity and death can occur.
  • Administer with caution and reduced dosage in patients with possible depletion of intravascular volume or history of hepatic impairment.
  • Store tablets at controlled room temperature (59° to 86°F).

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note history of anuria, lupus erythematosus, or kidney or liver disease.
  • Ensure that serum electrolytes are monitored periodically.
  • Monitor and record BP and pulse. Should hypotension result, old medication and notify health care provider.
  • Take safety precautionsif orthostatic hypotension occurs.
  • Monitor for sighns of hypersensitivity including angioedema involving swelling of the face, lips, eyelids, and tongue. Discontinue medication and notify health care provider immediately if noted.

 

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient to take prescribed dose once daily, without regard to meals.
  • Advise patient to try to take each dose at about the same time each day.
  • Inform patient that drug controls, but does not cure, hypertension, and to continue taking drug as prescribed even when BP is not elevated.
  • Caution patient not to change the dose or stop taking unless advised by health care provider.
  • Instruct patient in BP and pulse measurement skills.
  • Advise patient to monitor and record BP and pulse at home and to inform health care provider should abnormal measurements be noted. Also advise patient to take record of BP and pulse to each follow-up visit.
  • Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to lie or sit down if they experience dizziness or lightheadedness when standing.
  • Caution patient that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP, resulting in lightheadedness or fainting.
  • Emphasize to hypertensive patient importance of other modalities on BP: weight control, regular exercise, smoking cessation, moderate intake of alohol and salt.
  • Advise patient to contact health care provider if pregnant, planning to become pregnant, or breastfeeding.
  • Instruct patient to stop taking drug and immediately report any of these symptoms to health care provider: fainting; swelling of the face, lips, eyelids, or tongue.
  • Caution patient to not take any prescription or OTC medications, salt substitutes, or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and lab tests may be required to monitor therapy and to keep appointments.

Drug Precautions ::

(ihr-beh-SAHR-tan)
Avapro
Tablets: 75 mg
Tablets: 150 mg
Tablets: 300 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension; nephropathy in type 2 diabetes.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Hypertension

Adults: PO Start with 150 mg once daily; then titrate to 300 mg once daily as necessary.

Children (13 to 16 yr): PO Start with 150 mg once daily; then titrate patients requiring a further reduction in BP to 300 mg once daily.

Children (6 to 12 yr): PO Start with 75 mg once daily; then titrate patients requiring a further reduction in BP to 150 mg once daily.

Nephropathy in Type 2 Diabetes

Adults PO Titrate dose to 300 mg once daily.

Volume- and Salt-Depleted Patients

PO Start with 75 mg.

 

 Interactions

Lithium:

Plasma concentrations my be increased by irbesartan, resultingin an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CARDIOVASCULAR: Chest pain; tachycardia; edema. CNS: Headache; anxiety/nervousness; dizziness. GI: Diarrhea; dyspepsia/heartburn; abdominal pain; nausea/vomiting. RESPIRATORY: Upper respiratory infection; influenza; pharyngitis; rhinitis; sinus abnormality OTHER: Musculoskeletal pain/trauma; fatigue; UIT; rash.

 

 Precautions

Pregnancy: Category C (first trimester); Category D (second and third trimesters). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established in children younger than 6 yr. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hypotension: Initiation of antihypertensive therapy may cause symptomatic hypotension in patients with intravascular volume or sodium-depletion.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Give prescribed dose once daily with or without food.
  • Administer alone or in combination with other antihypertensives.
  • Do not administer to pregnant women because fetal and neonatal morbidity and death can occur.
  • Administer with caution and reduced dosage in patients with possible depletion of intravascular volume or history of hepatic impairment.
  • Store tablets at controlled room temperature (59° to 86°F).

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note history of anuria, lupus erythematosus, or kidney or liver disease.
  • Ensure that serum electrolytes are monitored periodically.
  • Monitor and record BP and pulse. Should hypotension result, old medication and notify health care provider.
  • Take safety precautionsif orthostatic hypotension occurs.
  • Monitor for sighns of hypersensitivity including angioedema involving swelling of the face, lips, eyelids, and tongue. Discontinue medication and notify health care provider immediately if noted.

 

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient to take prescribed dose once daily, without regard to meals.
  • Advise patient to try to take each dose at about the same time each day.
  • Inform patient that drug controls, but does not cure, hypertension, and to continue taking drug as prescribed even when BP is not elevated.
  • Caution patient not to change the dose or stop taking unless advised by health care provider.
  • Instruct patient in BP and pulse measurement skills.
  • Advise patient to monitor and record BP and pulse at home and to inform health care provider should abnormal measurements be noted. Also advise patient to take record of BP and pulse to each follow-up visit.
  • Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to lie or sit down if they experience dizziness or lightheadedness when standing.
  • Caution patient that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP, resulting in lightheadedness or fainting.
  • Emphasize to hypertensive patient importance of other modalities on BP: weight control, regular exercise, smoking cessation, moderate intake of alohol and salt.
  • Advise patient to contact health care provider if pregnant, planning to become pregnant, or breastfeeding.
  • Instruct patient to stop taking drug and immediately report any of these symptoms to health care provider: fainting; swelling of the face, lips, eyelids, or tongue.
  • Caution patient to not take any prescription or OTC medications, salt substitutes, or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and lab tests may be required to monitor therapy and to keep appointments.

Drug Side Effects ::

(ihr-beh-SAHR-tan)
Avapro
Tablets: 75 mg
Tablets: 150 mg
Tablets: 300 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension; nephropathy in type 2 diabetes.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Hypertension

Adults: PO Start with 150 mg once daily; then titrate to 300 mg once daily as necessary.

Children (13 to 16 yr): PO Start with 150 mg once daily; then titrate patients requiring a further reduction in BP to 300 mg once daily.

Children (6 to 12 yr): PO Start with 75 mg once daily; then titrate patients requiring a further reduction in BP to 150 mg once daily.

Nephropathy in Type 2 Diabetes

Adults PO Titrate dose to 300 mg once daily.

Volume- and Salt-Depleted Patients

PO Start with 75 mg.

 

 Interactions

Lithium:

Plasma concentrations my be increased by irbesartan, resultingin an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CARDIOVASCULAR: Chest pain; tachycardia; edema. CNS: Headache; anxiety/nervousness; dizziness. GI: Diarrhea; dyspepsia/heartburn; abdominal pain; nausea/vomiting. RESPIRATORY: Upper respiratory infection; influenza; pharyngitis; rhinitis; sinus abnormality OTHER: Musculoskeletal pain/trauma; fatigue; UIT; rash.

 

 Precautions

Pregnancy: Category C (first trimester); Category D (second and third trimesters). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established in children younger than 6 yr. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hypotension: Initiation of antihypertensive therapy may cause symptomatic hypotension in patients with intravascular volume or sodium-depletion.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Give prescribed dose once daily with or without food.
  • Administer alone or in combination with other antihypertensives.
  • Do not administer to pregnant women because fetal and neonatal morbidity and death can occur.
  • Administer with caution and reduced dosage in patients with possible depletion of intravascular volume or history of hepatic impairment.
  • Store tablets at controlled room temperature (59° to 86°F).

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note history of anuria, lupus erythematosus, or kidney or liver disease.
  • Ensure that serum electrolytes are monitored periodically.
  • Monitor and record BP and pulse. Should hypotension result, old medication and notify health care provider.
  • Take safety precautionsif orthostatic hypotension occurs.
  • Monitor for sighns of hypersensitivity including angioedema involving swelling of the face, lips, eyelids, and tongue. Discontinue medication and notify health care provider immediately if noted.

 

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient to take prescribed dose once daily, without regard to meals.
  • Advise patient to try to take each dose at about the same time each day.
  • Inform patient that drug controls, but does not cure, hypertension, and to continue taking drug as prescribed even when BP is not elevated.
  • Caution patient not to change the dose or stop taking unless advised by health care provider.
  • Instruct patient in BP and pulse measurement skills.
  • Advise patient to monitor and record BP and pulse at home and to inform health care provider should abnormal measurements be noted. Also advise patient to take record of BP and pulse to each follow-up visit.
  • Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to lie or sit down if they experience dizziness or lightheadedness when standing.
  • Caution patient that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP, resulting in lightheadedness or fainting.
  • Emphasize to hypertensive patient importance of other modalities on BP: weight control, regular exercise, smoking cessation, moderate intake of alohol and salt.
  • Advise patient to contact health care provider if pregnant, planning to become pregnant, or breastfeeding.
  • Instruct patient to stop taking drug and immediately report any of these symptoms to health care provider: fainting; swelling of the face, lips, eyelids, or tongue.
  • Caution patient to not take any prescription or OTC medications, salt substitutes, or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and lab tests may be required to monitor therapy and to keep appointments.

Drug Mode of Action ::  

(ihr-beh-SAHR-tan)
Avapro
Tablets: 75 mg
Tablets: 150 mg
Tablets: 300 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension; nephropathy in type 2 diabetes.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Hypertension

Adults: PO Start with 150 mg once daily; then titrate to 300 mg once daily as necessary.

Children (13 to 16 yr): PO Start with 150 mg once daily; then titrate patients requiring a further reduction in BP to 300 mg once daily.

Children (6 to 12 yr): PO Start with 75 mg once daily; then titrate patients requiring a further reduction in BP to 150 mg once daily.

Nephropathy in Type 2 Diabetes

Adults PO Titrate dose to 300 mg once daily.

Volume- and Salt-Depleted Patients

PO Start with 75 mg.

 

 Interactions

Lithium:

Plasma concentrations my be increased by irbesartan, resultingin an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CARDIOVASCULAR: Chest pain; tachycardia; edema. CNS: Headache; anxiety/nervousness; dizziness. GI: Diarrhea; dyspepsia/heartburn; abdominal pain; nausea/vomiting. RESPIRATORY: Upper respiratory infection; influenza; pharyngitis; rhinitis; sinus abnormality OTHER: Musculoskeletal pain/trauma; fatigue; UIT; rash.

 

 Precautions

Pregnancy: Category C (first trimester); Category D (second and third trimesters). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established in children younger than 6 yr. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hypotension: Initiation of antihypertensive therapy may cause symptomatic hypotension in patients with intravascular volume or sodium-depletion.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Give prescribed dose once daily with or without food.
  • Administer alone or in combination with other antihypertensives.
  • Do not administer to pregnant women because fetal and neonatal morbidity and death can occur.
  • Administer with caution and reduced dosage in patients with possible depletion of intravascular volume or history of hepatic impairment.
  • Store tablets at controlled room temperature (59° to 86°F).

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note history of anuria, lupus erythematosus, or kidney or liver disease.
  • Ensure that serum electrolytes are monitored periodically.
  • Monitor and record BP and pulse. Should hypotension result, old medication and notify health care provider.
  • Take safety precautionsif orthostatic hypotension occurs.
  • Monitor for sighns of hypersensitivity including angioedema involving swelling of the face, lips, eyelids, and tongue. Discontinue medication and notify health care provider immediately if noted.

 

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient to take prescribed dose once daily, without regard to meals.
  • Advise patient to try to take each dose at about the same time each day.
  • Inform patient that drug controls, but does not cure, hypertension, and to continue taking drug as prescribed even when BP is not elevated.
  • Caution patient not to change the dose or stop taking unless advised by health care provider.
  • Instruct patient in BP and pulse measurement skills.
  • Advise patient to monitor and record BP and pulse at home and to inform health care provider should abnormal measurements be noted. Also advise patient to take record of BP and pulse to each follow-up visit.
  • Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to lie or sit down if they experience dizziness or lightheadedness when standing.
  • Caution patient that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP, resulting in lightheadedness or fainting.
  • Emphasize to hypertensive patient importance of other modalities on BP: weight control, regular exercise, smoking cessation, moderate intake of alohol and salt.
  • Advise patient to contact health care provider if pregnant, planning to become pregnant, or breastfeeding.
  • Instruct patient to stop taking drug and immediately report any of these symptoms to health care provider: fainting; swelling of the face, lips, eyelids, or tongue.
  • Caution patient to not take any prescription or OTC medications, salt substitutes, or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and lab tests may be required to monitor therapy and to keep appointments.

Drug Interactions ::

(ihr-beh-SAHR-tan)
Avapro
Tablets: 75 mg
Tablets: 150 mg
Tablets: 300 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension; nephropathy in type 2 diabetes.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Hypertension

Adults: PO Start with 150 mg once daily; then titrate to 300 mg once daily as necessary.

Children (13 to 16 yr): PO Start with 150 mg once daily; then titrate patients requiring a further reduction in BP to 300 mg once daily.

Children (6 to 12 yr): PO Start with 75 mg once daily; then titrate patients requiring a further reduction in BP to 150 mg once daily.

Nephropathy in Type 2 Diabetes

Adults PO Titrate dose to 300 mg once daily.

Volume- and Salt-Depleted Patients

PO Start with 75 mg.

 

 Interactions

Lithium:

Plasma concentrations my be increased by irbesartan, resultingin an increase in the pharmacologic and adverse effects of lithium.

 

Drug Assesment ::

(ihr-beh-SAHR-tan)
Avapro
Tablets: 75 mg
Tablets: 150 mg
Tablets: 300 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension; nephropathy in type 2 diabetes.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Hypertension

Adults: PO Start with 150 mg once daily; then titrate to 300 mg once daily as necessary.

Children (13 to 16 yr): PO Start with 150 mg once daily; then titrate patients requiring a further reduction in BP to 300 mg once daily.

Children (6 to 12 yr): PO Start with 75 mg once daily; then titrate patients requiring a further reduction in BP to 150 mg once daily.

Nephropathy in Type 2 Diabetes

Adults PO Titrate dose to 300 mg once daily.

Volume- and Salt-Depleted Patients

PO Start with 75 mg.

 

 Interactions

Lithium:

Plasma concentrations my be increased by irbesartan, resultingin an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CARDIOVASCULAR: Chest pain; tachycardia; edema. CNS: Headache; anxiety/nervousness; dizziness. GI: Diarrhea; dyspepsia/heartburn; abdominal pain; nausea/vomiting. RESPIRATORY: Upper respiratory infection; influenza; pharyngitis; rhinitis; sinus abnormality OTHER: Musculoskeletal pain/trauma; fatigue; UIT; rash.

 

 Precautions

Pregnancy: Category C (first trimester); Category D (second and third trimesters). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established in children younger than 6 yr. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hypotension: Initiation of antihypertensive therapy may cause symptomatic hypotension in patients with intravascular volume or sodium-depletion.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Give prescribed dose once daily with or without food.
  • Administer alone or in combination with other antihypertensives.
  • Do not administer to pregnant women because fetal and neonatal morbidity and death can occur.
  • Administer with caution and reduced dosage in patients with possible depletion of intravascular volume or history of hepatic impairment.
  • Store tablets at controlled room temperature (59° to 86°F).

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note history of anuria, lupus erythematosus, or kidney or liver disease.
  • Ensure that serum electrolytes are monitored periodically.
  • Monitor and record BP and pulse. Should hypotension result, old medication and notify health care provider.
  • Take safety precautionsif orthostatic hypotension occurs.
  • Monitor for sighns of hypersensitivity including angioedema involving swelling of the face, lips, eyelids, and tongue. Discontinue medication and notify health care provider immediately if noted.

 

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient to take prescribed dose once daily, without regard to meals.
  • Advise patient to try to take each dose at about the same time each day.
  • Inform patient that drug controls, but does not cure, hypertension, and to continue taking drug as prescribed even when BP is not elevated.
  • Caution patient not to change the dose or stop taking unless advised by health care provider.
  • Instruct patient in BP and pulse measurement skills.
  • Advise patient to monitor and record BP and pulse at home and to inform health care provider should abnormal measurements be noted. Also advise patient to take record of BP and pulse to each follow-up visit.
  • Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to lie or sit down if they experience dizziness or lightheadedness when standing.
  • Caution patient that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP, resulting in lightheadedness or fainting.
  • Emphasize to hypertensive patient importance of other modalities on BP: weight control, regular exercise, smoking cessation, moderate intake of alohol and salt.
  • Advise patient to contact health care provider if pregnant, planning to become pregnant, or breastfeeding.
  • Instruct patient to stop taking drug and immediately report any of these symptoms to health care provider: fainting; swelling of the face, lips, eyelids, or tongue.
  • Caution patient to not take any prescription or OTC medications, salt substitutes, or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and lab tests may be required to monitor therapy and to keep appointments.

Drug Storage/Management ::

(ihr-beh-SAHR-tan)
Avapro
Tablets: 75 mg
Tablets: 150 mg
Tablets: 300 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension; nephropathy in type 2 diabetes.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Hypertension

Adults: PO Start with 150 mg once daily; then titrate to 300 mg once daily as necessary.

Children (13 to 16 yr): PO Start with 150 mg once daily; then titrate patients requiring a further reduction in BP to 300 mg once daily.

Children (6 to 12 yr): PO Start with 75 mg once daily; then titrate patients requiring a further reduction in BP to 150 mg once daily.

Nephropathy in Type 2 Diabetes

Adults PO Titrate dose to 300 mg once daily.

Volume- and Salt-Depleted Patients

PO Start with 75 mg.

 

 Interactions

Lithium:

Plasma concentrations my be increased by irbesartan, resultingin an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CARDIOVASCULAR: Chest pain; tachycardia; edema. CNS: Headache; anxiety/nervousness; dizziness. GI: Diarrhea; dyspepsia/heartburn; abdominal pain; nausea/vomiting. RESPIRATORY: Upper respiratory infection; influenza; pharyngitis; rhinitis; sinus abnormality OTHER: Musculoskeletal pain/trauma; fatigue; UIT; rash.

 

 Precautions

Pregnancy: Category C (first trimester); Category D (second and third trimesters). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established in children younger than 6 yr. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hypotension: Initiation of antihypertensive therapy may cause symptomatic hypotension in patients with intravascular volume or sodium-depletion.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Give prescribed dose once daily with or without food.
  • Administer alone or in combination with other antihypertensives.
  • Do not administer to pregnant women because fetal and neonatal morbidity and death can occur.
  • Administer with caution and reduced dosage in patients with possible depletion of intravascular volume or history of hepatic impairment.
  • Store tablets at controlled room temperature (59° to 86°F).

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note history of anuria, lupus erythematosus, or kidney or liver disease.
  • Ensure that serum electrolytes are monitored periodically.
  • Monitor and record BP and pulse. Should hypotension result, old medication and notify health care provider.
  • Take safety precautionsif orthostatic hypotension occurs.
  • Monitor for sighns of hypersensitivity including angioedema involving swelling of the face, lips, eyelids, and tongue. Discontinue medication and notify health care provider immediately if noted.

 

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient to take prescribed dose once daily, without regard to meals.
  • Advise patient to try to take each dose at about the same time each day.
  • Inform patient that drug controls, but does not cure, hypertension, and to continue taking drug as prescribed even when BP is not elevated.
  • Caution patient not to change the dose or stop taking unless advised by health care provider.
  • Instruct patient in BP and pulse measurement skills.
  • Advise patient to monitor and record BP and pulse at home and to inform health care provider should abnormal measurements be noted. Also advise patient to take record of BP and pulse to each follow-up visit.
  • Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to lie or sit down if they experience dizziness or lightheadedness when standing.
  • Caution patient that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP, resulting in lightheadedness or fainting.
  • Emphasize to hypertensive patient importance of other modalities on BP: weight control, regular exercise, smoking cessation, moderate intake of alohol and salt.
  • Advise patient to contact health care provider if pregnant, planning to become pregnant, or breastfeeding.
  • Instruct patient to stop taking drug and immediately report any of these symptoms to health care provider: fainting; swelling of the face, lips, eyelids, or tongue.
  • Caution patient to not take any prescription or OTC medications, salt substitutes, or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and lab tests may be required to monitor therapy and to keep appointments.

Drug Notes ::

(ihr-beh-SAHR-tan)
Avapro
Tablets: 75 mg
Tablets: 150 mg
Tablets: 300 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension; nephropathy in type 2 diabetes.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Hypertension

Adults: PO Start with 150 mg once daily; then titrate to 300 mg once daily as necessary.

Children (13 to 16 yr): PO Start with 150 mg once daily; then titrate patients requiring a further reduction in BP to 300 mg once daily.

Children (6 to 12 yr): PO Start with 75 mg once daily; then titrate patients requiring a further reduction in BP to 150 mg once daily.

Nephropathy in Type 2 Diabetes

Adults PO Titrate dose to 300 mg once daily.

Volume- and Salt-Depleted Patients

PO Start with 75 mg.

 

 Interactions

Lithium:

Plasma concentrations my be increased by irbesartan, resultingin an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CARDIOVASCULAR: Chest pain; tachycardia; edema. CNS: Headache; anxiety/nervousness; dizziness. GI: Diarrhea; dyspepsia/heartburn; abdominal pain; nausea/vomiting. RESPIRATORY: Upper respiratory infection; influenza; pharyngitis; rhinitis; sinus abnormality OTHER: Musculoskeletal pain/trauma; fatigue; UIT; rash.

 

 Precautions

Pregnancy: Category C (first trimester); Category D (second and third trimesters). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established in children younger than 6 yr. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hypotension: Initiation of antihypertensive therapy may cause symptomatic hypotension in patients with intravascular volume or sodium-depletion.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Give prescribed dose once daily with or without food.
  • Administer alone or in combination with other antihypertensives.
  • Do not administer to pregnant women because fetal and neonatal morbidity and death can occur.
  • Administer with caution and reduced dosage in patients with possible depletion of intravascular volume or history of hepatic impairment.
  • Store tablets at controlled room temperature (59° to 86°F).

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note history of anuria, lupus erythematosus, or kidney or liver disease.
  • Ensure that serum electrolytes are monitored periodically.
  • Monitor and record BP and pulse. Should hypotension result, old medication and notify health care provider.
  • Take safety precautionsif orthostatic hypotension occurs.
  • Monitor for sighns of hypersensitivity including angioedema involving swelling of the face, lips, eyelids, and tongue. Discontinue medication and notify health care provider immediately if noted.

 

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient to take prescribed dose once daily, without regard to meals.
  • Advise patient to try to take each dose at about the same time each day.
  • Inform patient that drug controls, but does not cure, hypertension, and to continue taking drug as prescribed even when BP is not elevated.
  • Caution patient not to change the dose or stop taking unless advised by health care provider.
  • Instruct patient in BP and pulse measurement skills.
  • Advise patient to monitor and record BP and pulse at home and to inform health care provider should abnormal measurements be noted. Also advise patient to take record of BP and pulse to each follow-up visit.
  • Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to lie or sit down if they experience dizziness or lightheadedness when standing.
  • Caution patient that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP, resulting in lightheadedness or fainting.
  • Emphasize to hypertensive patient importance of other modalities on BP: weight control, regular exercise, smoking cessation, moderate intake of alohol and salt.
  • Advise patient to contact health care provider if pregnant, planning to become pregnant, or breastfeeding.
  • Instruct patient to stop taking drug and immediately report any of these symptoms to health care provider: fainting; swelling of the face, lips, eyelids, or tongue.
  • Caution patient to not take any prescription or OTC medications, salt substitutes, or dietary supplements unless advised by health care provider.
  • Advise patient that follow-up visits and lab tests may be required to monitor therapy and to keep appointments.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

Leave a comment

Your email address will not be published. Required fields are marked *

royalmpo Royalmpo Royalmpo royalmpo royalmpo royalmpo royalmpo https://malangtoday.id/ https://guyonanbola.com/ renunganhariankatolik.web.id royalmpo royalmpo royalmpo dewaslot168 ri188 https://hayzlett.com/c-suite-network/ kingslot jkt88 mpodewa https://going-natural.com/the-story-behind-the-mutilated-scalp-video/ royalmpo/ pisang88/ langkahcurang/ mpohoki/ mpocuan/ royalmpo/ mporoyal/ asiaslot/ rajaslot138/ royalmpo https://hayzlett.com/news/ rajaslot88/ Analisis Scatter Hitam MahjongWays RTP Terukur Kemenangan Puluhan Grid Fase Awal Mahjong Pola Perilaku Pemain Harian Prediksi Strategi Game Terbaik RTP Strategi Target Kemenangan Tekanan Meja Live Kasino Slot Digital Hiburan Ringan Slot Online Tanpa Target Mengelola Mood Pemain Slot https://going-natural.com/my-braid-locs/ https://going-natural.com/kellen-marcus/ narutoslot bangslot royalmpo royalmpo macanasia bosslot slotking gacorway
Strategi Analitik Platform Game Dalam Mengelola Variasi Pola Permainan Online Di Era Windows 12 Pendekatan Data Driven Dalam Memahami Ritme Sistem Permainan Digital Pada Ekosistem Android Modern Studi Dinamika Platform Gaming Melalui Distribusi Kombinasi Simbol Di Tengah Popularitas Xbox Game Pass Analisis Strategi Modern Dalam Mengelola Volatilitas Sistem Permainan Digital Saat Tren Nintendo Kembali Naik Framework Pengolahan Data Gaming Untuk Menjaga Stabilitas Pola Permainan Dalam Era Gemini AI Tools Teori Permainan Mahjong Ways Dalam Analisa Intensitas Sistem RTP Online Pada Perangkat Smartphone Modern Pendekatan Sistematis Dalam Menganalisis Pola Permainan Pada Ekosistem Gaming Setelah Discord Down Model Evaluasi Strategi Platform Game Melalui Observasi Pergerakan Algoritma Setelah Update iOS 26.3.1 Strategi Adaptif Dalam Mengelola Ritme Permainan Pada Platform Digital Dengan Dukungan Windows 12 Pendekatan Data Analitik Untuk Mengidentifikasi Pola Sistem Permainan Mobile Pada Samsung Galaxy S26 Ultra
Studi Adaptasi Strategi Permainan Mahjong Dalam Sistem Platform Digital Di Tengah Tren Nintendo Gaming Analisis Teknologi Gaming Platform Dalam Evolusi Sistem Permainan Berbasis RTP Di Era Gemini AI Pendekatan Sistematik Dalam Analisis Algoritma Permainan Mobile Saat Dark Mode Twitter Kembali Trending Studi Pola Mahjong Ways Dalam Perspektif Strategi Platform Game Pada Perangkat Smartphone Modern Analisis Perkembangan Algoritma Platform Gaming Dalam Sistem Permainan Pada Era Xbox Game Pass Pendekatan Manajemen Risiko Permainan Mobile Dalam Ekosistem Gaming Android Generasi Baru Strategi Pengamatan Sistem Permainan Dalam Lingkungan Platform Game Modern Saat Windows 12 Dibahas Evaluasi Sistem Gaming Platform Dalam Mengelola Variasi Pola Permainan Pada Perangkat Samsung Galaxy Framework Analitik Permainan Digital Dalam Mengelola Variasi Sistem Game Saat Re9 Update Dibahas Gamer Studi Dinamika Platform Game Melalui Pendekatan Analisis Data Di Era Apple Newsroom Digital Model Framework Strategi Permainan Digital Dalam Platform Gaming Berbasis Android Modern Strategi Pengelolaan Sistem Permainan Melalui Pendekatan Data Analitik Pada Infrastruktur Cloud Gaming Analisis Adaptasi Sistem Permainan Dalam Ekosistem Gaming Digital Saat Project Helix Menjadi Sorotan Pendekatan Modern Dalam Analisis Pola Permainan Berbasis Data Saat Gemini AI Digunakan Developer Evaluasi Dinamika Sistem Permainan Digital Melalui Observasi Data Pada Sistem iOS 26.3.1 Studi Struktur Sistem Game Dalam Perspektif Teknologi Gaming Di Tengah Tren Nintendo Global Pendekatan Framework Gaming Dalam Mengelola Pola Permainan Digital Di Tengah Popularitas Mario Day Analisis Perubahan Pola Mahjong Wins Dalam Ekosistem Gaming Modern Saat Re9 Update Diperbincangkan Model Analitik Pola Permainan Mahjong Dalam Sistem Platform Digital Modern Berbasis Android Studi Evolusi Teknologi Gaming Dalam Pengembangan Platform Permainan Pada Sistem Windows 12 Strategi Modern Membaca Sistem Permainan Digital Berbasis Algoritma Pada Infrastruktur Cloud Gaming Evaluasi Sistem Platform Game Dalam Dinamika Permainan Online Pada Era Smartphone Modern Pendekatan Data Platform Dalam Mengidentifikasi Pola Permainan Online Pada Infrastruktur TV App Strategi Pengolahan Data Gaming Dalam Mengelola Pola Permainan RTP Pada Infrastruktur Gaming Cloud Strategi Pengelolaan Pola Permainan Melalui Analisis Platform Digital Saat iPhone Generasi Baru Dirilis Pendekatan Analitik Sistem Game Dalam Mengelola Ritme Permainan Pada Era Xbox Game Pass Strategi Data Driven Dalam Menganalisis Pola Sistem Permainan Digital Pada Infrastruktur Cloud Studi Algoritma Permainan Mahjong Dalam Perspektif Platform Gaming Pada Ekosistem Android Analisis Sistem Permainan Digital Dalam Kerangka Strategi Platform Game Di Era Apple Ecosystem Dinamika Sistem Permainan Mahjong Digital Melalui Observasi Ritme Algoritma Pada Ekosistem Gaming Mobile Modern Pola Mahjong Ways 2 Hari Ini Strategi Malam Mahjong Wins 3 Kisah Sukses Andi Grid Mahjong & Starlight Saksi Mata: Mode Manual Mahjong Wins RTP Bertahap Pragmatic Spiral Pola Mahjong Ways Kurikulum Jackpot Respon Mahjong Wins 3 Lebih Cepat Akselerasi Free Spin Mahjong Wins3